INmune Bio Balance Sheet Health
Financial Health criteria checks 4/6
INmune Bio has a total shareholder equity of $38.7M and total debt of $2.5M, which brings its debt-to-equity ratio to 6.4%. Its total assets and total liabilities are $52.8M and $14.1M respectively.
Key information
6.4%
Debt to equity ratio
US$2.49m
Debt
| Interest coverage ratio | n/a |
| Cash | US$33.55m |
| Equity | US$38.68m |
| Total liabilities | US$14.11m |
| Total assets | US$52.78m |
Recent financial health updates
Is INmune Bio (NASDAQ:INMB) Using Debt In A Risky Way?
Nov 03
Is INmune Bio (NASDAQ:INMB) Using Debt Sensibly?
Jan 19Is INmune Bio (NASDAQ:INMB) Using Debt In A Risky Way?
Sep 04Is INmune Bio (NASDAQ:INMB) Using Too Much Debt?
May 12Here's Why INmune Bio (NASDAQ:INMB) Can Manage Its Debt Despite Losing Money
Jan 16Here's Why INmune Bio (NASDAQ:INMB) Can Manage Its Debt Despite Losing Money
Jul 11Recent updates
Is INmune Bio (NASDAQ:INMB) Using Debt In A Risky Way?
Nov 03INmune Bio: NK Cell Therapy INKmune For mCRPC Is Another Shot On Goal
Sep 30It's Unlikely That Shareholders Will Increase INmune Bio, Inc.'s (NASDAQ:INMB) Compensation By Much This Year
Jul 12Is INmune Bio (NASDAQ:INMB) Using Debt Sensibly?
Jan 19Is INmune Bio (NASDAQ:INMB) Using Debt In A Risky Way?
Sep 04Is INmune Bio (NASDAQ:INMB) Using Too Much Debt?
May 12Here's Why INmune Bio (NASDAQ:INMB) Can Manage Its Debt Despite Losing Money
Jan 16Here's Why INmune Bio (NASDAQ:INMB) Can Manage Its Debt Despite Losing Money
Jul 11INmune Bio: Possibly The Once In A Lifetime Dip
May 25INmune Bio: Speculative Biotech With 2 Solid Potential Approaches To Treating AD And Solid Tumors
Apr 05Is INmune Bio (NASDAQ:INMB) A Risky Investment?
Mar 25Financial Position Analysis
Short Term Liabilities: INMB's short term assets ($35.9M) exceed its short term liabilities ($13.8M).
Long Term Liabilities: INMB's short term assets ($35.9M) exceed its long term liabilities ($284.0K).
Debt to Equity History and Analysis
Debt Level: INMB has more cash than its total debt.
Reducing Debt: INMB's debt to equity ratio has increased from 0% to 6.4% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: INMB has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: INMB has less than a year of cash runway if free cash flow continues to reduce at historical rates of 25.7% each year
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 12:43 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
INmune Bio, Inc. is covered by 9 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| James Molloy | Alliance Global Partners |
| Joel Beatty | Baird |
| Mayank Mamtani | B. Riley Securities, Inc. |